カテゴリー： Market Monitor Global, 世界, 医療/バイオ

チェックポイント阻害薬難治性がんの世界市場見通し2023年-2029年

◆英語タイトル：Checkpoint Inhibitor Refractory Cancer Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2170）◆商品コード：MMG23FB2170
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：106
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のチェックポイント阻害薬難治性がん市場規模と予測を収録しています。・世界のチェックポイント阻害薬難治性がん市場：売上、2018年-2023年、2024年-2029年
・世界のチェックポイント阻害薬難治性がん市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のチェックポイント阻害薬難治性がん市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「PD-1阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

チェックポイント阻害薬難治性がんのグローバル主要企業は、Bristol-Myers Squibb、AstraZeneca、Merck、Roche、Regeneron Pharmaceuticals、Bristol-Myers Squibb、Janssen Research and Development、4D pharma、4SC AG、OncoSec Medical、Mirati Therapeutics、Ascentage Pharma Group、ENB Therapeutics、Exicure、Eisai、Kartos Therapeutics、Exelixis、ImmunityBioなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、チェックポイント阻害薬難治性がんのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のチェックポイント阻害薬難治性がん市場：タイプ別、2018年-2023年、2024年-2029年
世界のチェックポイント阻害薬難治性がん市場：タイプ別市場シェア、2022年
・PD-1阻害剤、PD-L1阻害剤

世界のチェックポイント阻害薬難治性がん市場：用途別、2018年-2023年、2024年-2029年
世界のチェックポイント阻害薬難治性がん市場：用途別市場シェア、2022年
・ホジキンリンパ腫、腎がん、黒色腫、非小細胞肺がん、その他

世界のチェックポイント阻害薬難治性がん市場：地域・国別、2018年-2023年、2024年-2029年
世界のチェックポイント阻害薬難治性がん市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるチェックポイント阻害薬難治性がんのグローバル売上、2018年-2023年
・主要企業におけるチェックポイント阻害薬難治性がんのグローバル売上シェア、2022年
・主要企業におけるチェックポイント阻害薬難治性がんのグローバル販売量、2018年-2023年
・主要企業におけるチェックポイント阻害薬難治性がんのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Bristol-Myers Squibb、AstraZeneca、Merck、Roche、Regeneron Pharmaceuticals、Bristol-Myers Squibb、Janssen Research and Development、4D pharma、4SC AG、OncoSec Medical、Mirati Therapeutics、Ascentage Pharma Group、ENB Therapeutics、Exicure、Eisai、Kartos Therapeutics、Exelixis、ImmunityBio

*************************************************************

・調査・分析レポートの概要
チェックポイント阻害薬難治性がん市場の定義
市場セグメント
世界のチェックポイント阻害薬難治性がん市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のチェックポイント阻害薬難治性がん市場規模
世界のチェックポイント阻害薬難治性がん市場規模：2022年 VS 2029年
世界のチェックポイント阻害薬難治性がん市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのチェックポイント阻害薬難治性がんの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のチェックポイント阻害薬難治性がん製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：PD-1阻害剤、PD-L1阻害剤
チェックポイント阻害薬難治性がんのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：ホジキンリンパ腫、腎がん、黒色腫、非小細胞肺がん、その他
チェックポイント阻害薬難治性がんの用途別グローバル売上・予測

・地域別市場分析
地域別チェックポイント阻害薬難治性がん市場規模 2022年と2029年
地域別チェックポイント阻害薬難治性がん売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Bristol-Myers Squibb、AstraZeneca、Merck、Roche、Regeneron Pharmaceuticals、Bristol-Myers Squibb、Janssen Research and Development、4D pharma、4SC AG、OncoSec Medical、Mirati Therapeutics、Ascentage Pharma Group、ENB Therapeutics、Exicure、Eisai、Kartos Therapeutics、Exelixis、ImmunityBio
...

This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitor Refractory Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitor Refractory Cancer. This report contains market size and forecasts of Checkpoint Inhibitor Refractory Cancer in global, including the following market information:
Global Checkpoint Inhibitor Refractory Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Checkpoint Inhibitor Refractory Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
PD-1 Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Checkpoint Inhibitor Refractory Cancer include Bristol-Myers Squibb, AstraZeneca, Merck, Roche, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Janssen Research and Development, 4D pharma and 4SC AG, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Checkpoint Inhibitor Refractory Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Checkpoint Inhibitor Refractory Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Checkpoint Inhibitor Refractory Cancer Market Segment Percentages, by Type, 2022 (%)
PD-1 Inhibitors
PD-L1 Inhibitors
Global Checkpoint Inhibitor Refractory Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Checkpoint Inhibitor Refractory Cancer Market Segment Percentages, by Application, 2022 (%)
Hodgkin Lymphoma
Kidney Cancer
Melanoma
Non-Small Cell Lung Cancer
Others
Global Checkpoint Inhibitor Refractory Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Checkpoint Inhibitor Refractory Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Checkpoint Inhibitor Refractory Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Checkpoint Inhibitor Refractory Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
AstraZeneca
Merck
Roche
Regeneron Pharmaceuticals
Bristol-Myers Squibb
Janssen Research and Development
4D pharma
4SC AG
OncoSec Medical
Mirati Therapeutics
Ascentage Pharma Group
ENB Therapeutics
Exicure
Eisai
Kartos Therapeutics
Exelixis
ImmunityBio
Outline of Major Chapters:
Chapter 1: Introduces the definition of Checkpoint Inhibitor Refractory Cancer, market overview.
Chapter 2: Global Checkpoint Inhibitor Refractory Cancer market size in revenue.
Chapter 3: Detailed analysis of Checkpoint Inhibitor Refractory Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Checkpoint Inhibitor Refractory Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Checkpoint Inhibitor Refractory Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Checkpoint Inhibitor Refractory Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Checkpoint Inhibitor Refractory Cancer Overall Market Size
2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size: 2022 VS 2029
2.2 Global Checkpoint Inhibitor Refractory Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Checkpoint Inhibitor Refractory Cancer Players in Global Market
3.2 Top Global Checkpoint Inhibitor Refractory Cancer Companies Ranked by Revenue
3.3 Global Checkpoint Inhibitor Refractory Cancer Revenue by Companies
3.4 Top 3 and Top 5 Checkpoint Inhibitor Refractory Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Checkpoint Inhibitor Refractory Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Checkpoint Inhibitor Refractory Cancer Players in Global Market
3.6.1 List of Global Tier 1 Checkpoint Inhibitor Refractory Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Checkpoint Inhibitor Refractory Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Checkpoint Inhibitor Refractory Cancer Market Size Markets, 2022 & 2029
4.1.2 PD-1 Inhibitors
4.1.3 PD-L1 Inhibitors
4.2 By Type – Global Checkpoint Inhibitor Refractory Cancer Revenue & Forecasts
4.2.1 By Type – Global Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2023
4.2.2 By Type – Global Checkpoint Inhibitor Refractory Cancer Revenue, 2024-2029
4.2.3 By Type – Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Checkpoint Inhibitor Refractory Cancer Market Size, 2022 & 2029
5.1.2 Hodgkin Lymphoma
5.1.3 Kidney Cancer
5.1.4 Melanoma
5.1.5 Non-Small Cell Lung Cancer
5.1.6 Others
5.2 By Application – Global Checkpoint Inhibitor Refractory Cancer Revenue & Forecasts
5.2.1 By Application – Global Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2023
5.2.2 By Application – Global Checkpoint Inhibitor Refractory Cancer Revenue, 2024-2029
5.2.3 By Application – Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Checkpoint Inhibitor Refractory Cancer Market Size, 2022 & 2029
6.2 By Region – Global Checkpoint Inhibitor Refractory Cancer Revenue & Forecasts
6.2.1 By Region – Global Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2023
6.2.2 By Region – Global Checkpoint Inhibitor Refractory Cancer Revenue, 2024-2029
6.2.3 By Region – Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.3.2 US Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.3.3 Canada Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.3.4 Mexico Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.4.2 Germany Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.3 France Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.4 U.K. Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.5 Italy Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.6 Russia Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.8 Benelux Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.5.2 China Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.3 Japan Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.4 South Korea Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.6 India Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.6.2 Brazil Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.6.3 Argentina Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.7.2 Turkey Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7.3 Israel Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7.5 UAE Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
7 Checkpoint Inhibitor Refractory Cancer Companies Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.1.4 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.1.5 Bristol-Myers Squibb Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.2.4 AstraZeneca Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.3.4 Merck Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.3.5 Merck Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.4.4 Roche Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Regeneron Pharmaceuticals
7.5.1 Regeneron Pharmaceuticals Company Summary
7.5.2 Regeneron Pharmaceuticals Business Overview
7.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.5.4 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.5.5 Regeneron Pharmaceuticals Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.6.4 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Janssen Research and Development
7.7.1 Janssen Research and Development Company Summary
7.7.2 Janssen Research and Development Business Overview
7.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.7.4 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.7.5 Janssen Research and Development Key News & Latest Developments
7.8 4D pharma
7.8.1 4D pharma Company Summary
7.8.2 4D pharma Business Overview
7.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.8.4 4D pharma Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.8.5 4D pharma Key News & Latest Developments
7.9 4SC AG
7.9.1 4SC AG Company Summary
7.9.2 4SC AG Business Overview
7.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.9.4 4SC AG Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.9.5 4SC AG Key News & Latest Developments
7.10 OncoSec Medical
7.10.1 OncoSec Medical Company Summary
7.10.2 OncoSec Medical Business Overview
7.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.10.4 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.10.5 OncoSec Medical Key News & Latest Developments
7.11 Mirati Therapeutics
7.11.1 Mirati Therapeutics Company Summary
7.11.2 Mirati Therapeutics Business Overview
7.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.11.4 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.11.5 Mirati Therapeutics Key News & Latest Developments
7.12 Ascentage Pharma Group
7.12.1 Ascentage Pharma Group Company Summary
7.12.2 Ascentage Pharma Group Business Overview
7.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.12.4 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.12.5 Ascentage Pharma Group Key News & Latest Developments
7.13 ENB Therapeutics
7.13.1 ENB Therapeutics Company Summary
7.13.2 ENB Therapeutics Business Overview
7.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.13.4 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.13.5 ENB Therapeutics Key News & Latest Developments
7.14 Exicure
7.14.1 Exicure Company Summary
7.14.2 Exicure Business Overview
7.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.14.4 Exicure Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.14.5 Exicure Key News & Latest Developments
7.15 Eisai
7.15.1 Eisai Company Summary
7.15.2 Eisai Business Overview
7.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.15.4 Eisai Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.15.5 Eisai Key News & Latest Developments
7.16 Kartos Therapeutics
7.16.1 Kartos Therapeutics Company Summary
7.16.2 Kartos Therapeutics Business Overview
7.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.16.4 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.16.5 Kartos Therapeutics Key News & Latest Developments
7.17 Exelixis
7.17.1 Exelixis Company Summary
7.17.2 Exelixis Business Overview
7.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.17.4 Exelixis Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.17.5 Exelixis Key News & Latest Developments
7.18 ImmunityBio
7.18.1 ImmunityBio Company Summary
7.18.2 ImmunityBio Business Overview
7.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.18.4 ImmunityBio Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.18.5 ImmunityBio Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ チェックポイント阻害薬難治性がんの世界市場見通し2023年-2029年(Checkpoint Inhibitor Refractory Cancer Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 乳がん免疫療法のグローバル市場展望 2023年-2029年：モノクローナル抗体、免疫チェックポイント阻害剤、がんワクチン、その他
  • JAK1阻害剤のグローバル市場展望 2023年-2029年：口腔、クリーム
  • 腫瘍免疫チェックポイント阻害剤療法のグローバル市場予測2023-2029
  • 乳がんホルモン療法の世界市場見通し2023年-2029年
  • RdRp阻害剤&3CLプロテアーゼ阻害剤の世界市場見通し2023年-2029年